NLS Pharmaceutics prices $0.79M direct offering
Ticker: NCEL · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.24, $786,660, $50,000, $0.30 |
| Sentiment | neutral |
Sentiment: neutral
Topics: registered-direct-offering, financing, dilution
TL;DR
NLS Pharma raising $0.79M via direct offering at $0.24/share, closing July 1st.
AI Summary
NLS Pharmaceutics Ltd. announced on June 28, 2024, a registered direct offering to issue 3,277,750 common shares at $0.24 per share. The offering is expected to close around July 1, 2024, subject to closing conditions.
Why It Matters
This registered direct offering provides NLS Pharmaceutics with capital, potentially to fund its ongoing operations and development of its pharmaceutical products.
Risk Assessment
Risk Level: medium — The company is issuing new shares at a low price, which could dilute existing shareholders and indicates potential capital needs.
Key Numbers
- $0.79M — Offering Size (Calculated from 3,277,750 shares at $0.24 per share)
- $0.24 — Share Price (Price per share in the registered direct offering)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company issuing shares
- June 28, 2024 (date) — Date of securities purchase agreement
- 3,277,750 (number) — Number of common shares to be issued
- CHF 0.02 (dollar_amount) — Par value per common share
- $0.24 (dollar_amount) — Purchase price per common share
- July 1, 2024 (date) — Expected closing date of the offering
FAQ
What is the total amount of capital NLS Pharmaceutics expects to raise from this offering?
NLS Pharmaceutics expects to raise approximately $0.79 million from the sale of 3,277,750 common shares at a purchase price of $0.24 per share.
When is the registered direct offering expected to close?
The offering is expected to close on or about July 1, 2024.
What type of securities are being offered in this registered direct offering?
The offering involves the issuance of common shares, with a par value of CHF 0.02 per share.
What is the purchase price per common share in this offering?
The purchase price for each common share is $0.24.
What is the number of common shares NLS Pharmaceutics is issuing in this offering?
NLS Pharmaceutics is issuing 3,277,750 common shares.
Filing Stats: 1,420 words · 6 min read · ~5 pages · Grade level 13.6 · Accepted 2024-07-01 08:09:37
Key Financial Figures
- $0.24 — e Common Shares, at a purchase price of $0.24 per share. The offering is expected to
- $786,660 — ult in gross proceeds to the Company of $786,660. The Company intends to use the net pro
- $50,000 — the securities sold in the offering and $50,000 for accountable expenses. In addition,
- $0.30 — ll each have an exercise price equal to $0.30 per share. The Series A Placement Agent
Filing Documents
- ea0208723-6k_nlspharma.htm (6-K) — 22KB
- ea020872301ex4-1_nlspharma.htm (EX-4.1) — 87KB
- ea020872301ex4-2_nlspharma.htm (EX-4.2) — 87KB
- ea020872301ex4-3_nlspharma.htm (EX-4.3) — 87KB
- ea020872301ex5-1_nlspharma.htm (EX-5.1) — 25KB
- ea020872301ex10-1_nlspharma.htm (EX-10.1) — 255KB
- ea020872301ex99-1_nlspharma.htm (EX-99.1) — 15KB
- ex5-1_001.jpg (GRAPHIC) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-057569.txt ( ) — 610KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: July 1, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 4